Home > Insider Trading > Filing (0001209191-17-031484)

Filing Details

Accession Number:: 0001209191-17-031484
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-05-11 14:02:39
Reporting Period:: 2017-05-09

Filing Date:: 2017-05-11
Accepted Time:: 2017-05-11 14:02:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510580	Kite Pharma Inc.	KITE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1609805	Ran Nussbaum	C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-05-09	3,520	$69.17	3,520	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2017-05-09	2,651	$69.17	2,651	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2017-05-09	1,029	$69.17	1,029	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2017-05-09	2,632	$68.94	2,632	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,950	Direct

Footnotes

The 7,200 shares acquired by the Pontifax entities were purchased in a block trade consisting of multiple transactions at prices ranging from $69.11 to 69.20, inclusive. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The securities are held in the name of Pontifax (Cayman) II L.P.
The reporting person is a director of Pontifax Management 2 G.P. (2007) Ltd., which is the general partner of Pontifax Management II L.P., which is the general partner of Pontifax (Cayman) II, L.P., Pontifax (Israel) II, L.P. and Pontifax (Israel) II - Individual Investors, L.P.
The securities are held in the name of Pontifax (Israel) II, L.P.
The securities are held in the name of Pontifax (Israel) II - Individual Investors L.P.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $68.47 to $68.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The shares are held in the name of Magna 100 Ltd., of which the reporting person is President and Sultan.